Adverum Biotechnologies Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last year. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Adverum Biotechnologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADVM, but not buy additional shares or sell existing shares.
View analyst ratings for Adverum Biotechnologies or view top-rated stocks.

Wall Street analysts have given Adverum Biotechnologies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adverum Biotechnologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Adverum Biotechnologies.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) posted its earnings results on Wednesday, May, 5th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.09. The biotechnology company earned $7.50 million during the quarter, compared to the consensus estimate of $0.46 million.
View Adverum Biotechnologies' earnings history.

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ADVM shares have decreased by 59.8% and is now trading at $3.72.
View which stocks have been most impacted by COVID-19.

10 brokers have issued 1-year price objectives for Adverum Biotechnologies' stock. Their forecasts range from $5.00 to $36.00. On average, they expect Adverum Biotechnologies' share price to reach $14.13 in the next year. This suggests a possible upside of 279.7% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies or view top-rated stocks among Wall Street analysts.

3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Glassdoor.com. Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees.

Some companies that are related to Adverum Biotechnologies include Krystal Biotech (KRYS), Cortexyme (CRTX), AlloVir (ALVR), Cullinan Oncology (CGEM), Aligos Therapeutics (ALGS), Ocugen (OCGN), Atara Biotherapeutics (ATRA), Agenus (AGEN), Vaxcyte (PCVX), Mesoblast (MESO), Coherus BioSciences (CHRS), Scholar Rock (SRRK), Forma Therapeutics (FMTX), Vaxart (VXRT) and Immunovant (IMVT).
View all of ADVM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Adverum Biotechnologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.56%), RTW Investments LP (7.50%), BlackRock Inc. (7.38%), Versant Venture Management LLC (5.18%), UBS Group AG (3.37%) and JPMorgan Chase & Co. (2.02%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Laurent Fischer, Leone D Patterson, Mehdi Gasmi, Patrick Machado and Peter Soparkar.
View institutional ownership trends for Adverum Biotechnologies.

ADVM stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Dimensional Fund Advisors LP, WS Management Lllp, RA Capital Management L.P., Barclays PLC, Stenahm Asset Managment Ltd, Man Group plc, and Northern Trust Corp. Company insiders that have sold Adverum Biotechnologies company stock in the last year include Leone D Patterson, and Mehdi Gasmi.
View insider buying and selling activity for Adverum Biotechnologies or view top insider-selling stocks.

ADVM stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., UBS Group AG, Rafferty Asset Management LLC, Citigroup Inc., BlackRock Inc., Geode Capital Management LLC, Renaissance Technologies LLC, and RTW Investments LP. Company insiders that have bought Adverum Biotechnologies stock in the last two years include James Paul Scopa, Laurent Fischer, Patrick Machado, and Peter Soparkar.
View insider buying and selling activity for Adverum Biotechnologies or or view top insider-buying stocks.

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ADVM stock can currently be purchased for approximately $3.72.

Adverum Biotechnologies has a market capitalization of $364.32 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-117,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

Adverum Biotechnologies employs 167 workers across the globe.

The official website for Adverum Biotechnologies is www.adverum.com.

Adverum Biotechnologies is headquartered at 800 Saginaw Drive, Redwood City CA, 94063.

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected]